Clinical Trials Browser

INDUSTRY × Interventional × Maximum Tolerated Dose × Clear all

NCT03838367 2025-09-09

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Phase 1/2 Terminated

10 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT02994953 2024-09-20

COMBO

Phase 1 Terminated

52 enrolled 34 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01647711 2017-01-31

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Phase 1 Completed

35 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung